BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

December 7, 2020

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2027

Conditions
Breast Cancer
Interventions
RADIATION

Hypofractionated radiotherapy

Radiation boost (RT) 7 Gy x 1 fraction on Day -14/Day -7 (arm 1) or Day -7/Day -14

DRUG

Pembrolizumab infusion

Pembrolizumab infusion flat dosing 200 mg delivered over 30 minutes.

PROCEDURE

Blood and tissue sampling

Blood will be collected for laboratory studies and complete correlative studies to examine how the subject's immune system is responding to treatment. On day 0, samples of tumor and any lymph nodes removed from armpit will be analyzed by the UPenn Department of Pathology according to standard practice.

Trial Locations (1)

19104

RECRUITING

Perelman Center for Advanced Medicine, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER